Taiwan · Delayed Price · Currency is TWD PharmaEngine Statistics
Total Valuation
PharmaEngine has a market cap or net worth of TWD 10.43 billion. The enterprise value is 5.84 billion.
| Market Cap | 10.43B |
| Enterprise Value | 5.84B |
Important Dates
The last earnings date was Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | Aug 13, 2025 |
Share Statistics
PharmaEngine has 143.68 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Current Share Class | 143.68M |
| Shares Outstanding | 143.68M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 6.06% |
| Float | 93.43M |
Valuation Ratios
The trailing PE ratio is 6.24 and the forward PE ratio is 26.81.
| PE Ratio | 6.24 |
| Forward PE | 26.81 |
| PS Ratio | 4.16 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | 6.07 |
| P/OCF Ratio | 6.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.86, with an EV/FCF ratio of 3.40.
| EV / Earnings | 3.49 |
| EV / Sales | 2.33 |
| EV / EBITDA | 2.86 |
| EV / EBIT | 2.88 |
| EV / FCF | 3.40 |
Financial Position
The company has a current ratio of 43.53, with a Debt / Equity ratio of 0.00.
| Current Ratio | 43.53 |
| Quick Ratio | 43.26 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 21,167.52 |
Financial Efficiency
Return on equity (ROE) is 38.17% and return on invested capital (ROIC) is 28.90%.
| Return on Equity (ROE) | 38.17% |
| Return on Assets (ROA) | 28.33% |
| Return on Invested Capital (ROIC) | 28.90% |
| Return on Capital Employed (ROCE) | 42.38% |
| Revenue Per Employee | 56.93M |
| Profits Per Employee | 38.06M |
| Employee Count | 44 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.15 |
Taxes
In the past 12 months, PharmaEngine has paid 439.34 million in taxes.
| Income Tax | 439.34M |
| Effective Tax Rate | 20.78% |
Stock Price Statistics
The stock price has decreased by -23.26% in the last 52 weeks. The beta is 0.18, so PharmaEngine's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -23.26% |
| 50-Day Moving Average | 69.69 |
| 200-Day Moving Average | 81.19 |
| Relative Strength Index (RSI) | 54.70 |
| Average Volume (20 Days) | 579,231 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEngine had revenue of TWD 2.51 billion and earned 1.67 billion in profits. Earnings per share was 11.63.
| Revenue | 2.51B |
| Gross Profit | 2.46B |
| Operating Income | 2.03B |
| Pretax Income | 2.11B |
| Net Income | 1.67B |
| EBITDA | 2.03B |
| EBIT | 2.03B |
| Earnings Per Share (EPS) | 11.63 |
Balance Sheet
The company has 4.59 billion in cash and 2.64 million in debt, giving a net cash position of 4.59 billion or 31.93 per share.
| Cash & Cash Equivalents | 4.59B |
| Total Debt | 2.64M |
| Net Cash | 4.59B |
| Net Cash Per Share | 31.93 |
| Equity (Book Value) | 4.79B |
| Book Value Per Share | 33.37 |
| Working Capital | 4.78B |
Cash Flow
In the last 12 months, operating cash flow was 1.72 billion and capital expenditures -389,000, giving a free cash flow of 1.72 billion.
| Operating Cash Flow | 1.72B |
| Capital Expenditures | -389,000 |
| Free Cash Flow | 1.72B |
| FCF Per Share | 11.97 |
Margins
Gross margin is 98.07%, with operating and profit margins of 81.12% and 66.86%.
| Gross Margin | 98.07% |
| Operating Margin | 81.12% |
| Pretax Margin | 84.40% |
| Profit Margin | 66.86% |
| EBITDA Margin | 81.19% |
| EBIT Margin | 81.12% |
| FCF Margin | 68.63% |
Dividends & Yields
This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 8.26%.
| Dividend Per Share | 6.00 |
| Dividend Yield | 8.26% |
| Dividend Growth (YoY) | 300.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 51.46% |
| Buyback Yield | -0.17% |
| Shareholder Yield | 8.09% |
| Earnings Yield | 16.06% |
| FCF Yield | 16.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2017. It was a forward split with a ratio of 1.1999616012.
| Last Split Date | Jul 26, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1999616012 |
Scores
PharmaEngine has an Altman Z-Score of 71.44 and a Piotroski F-Score of 6.
| Altman Z-Score | 71.44 |
| Piotroski F-Score | 6 |